Clinical Trial Update: Efficiency Study of Low Dose of IL-2 to Prevent Relapse in Standard Risk Leukemia After Transplantation [NA]

View source ↗

Summary

A clinical trial evaluating low-dose interleukin-2 to prevent relapse in standard-risk leukemia after transplantation has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia

Drugs mentioned

• Aldesleukin (interleukin-2)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Leukemia | NA | Status: TERMINATED